PMID- 34745983
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220428
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 11
DP  - 2021
TI  - PD-L1, Mismatch Repair Protein, and NTRK Immunohistochemical Expression in 
      Cervical Small Cell Neuroendocrine Carcinoma.
PG  - 752453
LID - 10.3389/fonc.2021.752453 [doi]
LID - 752453
AB  - BACKGROUND: Cervical small cell neuroendocrine carcinoma (SCNC) is a rare and 
      aggressive disease that lacks a standard treatment strategy or effective methods 
      of targeted therapy. PD-L1 inhibitors for DNA mismatch repair system-deficient 
      (dMMR) tumors and neurotrophin receptor tyrosine kinase (NTRK) inhibitors offer 
      potential pan-cancer treatments. METHODS: Immunohistochemistry was employed as 
      the main detection method, and any NTRK positive cases, identified by 
      immunohistochemistry, were further submitted for evaluation by fluorescence in 
      situ hybridization (FISH) and real-time polymerase chain reaction (RT-PCR) 
      methods. RESULTS: Forty-six patients were enrolled. Positive PD-L1 expression was 
      seen in 22 of the 43 patients (51.16%) with an average combined positive score of 
      6.82. PD-L1-positive patients were more likely to have a higher proliferation 
      rate in the tumor, and they experienced less recurrence and death (p = 0.048 and 
      0.033, respectively) compared with the patients with negative PD-L1 expression. 
      However, in the multivariate analysis, none of the clinical parameters was 
      associated with the expression of PD-L1. There was no association between PD-L1 
      expression and disease recurrence or overall survival in the Kaplan-Meier 
      analysis. All cases were found to be MMR-stable and lacked NTRK gene fusion. 
      However, pan-Trk expressed in 14 (32.56%) of the 43 tested cases, but FISH and 
      RT-PCR failed to confirm any positive fusion signals in IHC-positive cases. 
      CONCLUSIONS: PD-L1 may be an effective therapeutic target for cervical SCNC. 
      Cervical SCNC is a MMR-stable tumor and lacks NTRK gene fusion. IHC isn't a 
      reliable method in the detection of NTRK gene fusion in cervical SCNC.
CI  - Copyright (c) 2021 Chen, Yang, Feng, Wu, Li, Pang, Shi and Liang.
FAU - Chen, Longyun
AU  - Chen L
AD  - Department of Pathology, State Key Laboratory of Complex Severe and Rare Disease, 
      Molecular Pathology Research Center, Peking Union Medical College Hospital, 
      Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 
      China.
FAU - Yang, Fan
AU  - Yang F
AD  - Department of Pathology, State Key Laboratory of Complex Severe and Rare Disease, 
      Molecular Pathology Research Center, Peking Union Medical College Hospital, 
      Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 
      China.
FAU - Feng, Ting
AU  - Feng T
AD  - Department of Pathology, State Key Laboratory of Complex Severe and Rare Disease, 
      Molecular Pathology Research Center, Peking Union Medical College Hospital, 
      Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 
      China.
FAU - Wu, Shafei
AU  - Wu S
AD  - Department of Pathology, State Key Laboratory of Complex Severe and Rare Disease, 
      Molecular Pathology Research Center, Peking Union Medical College Hospital, 
      Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 
      China.
FAU - Li, Kaimi
AU  - Li K
AD  - Department of Pathology, State Key Laboratory of Complex Severe and Rare Disease, 
      Molecular Pathology Research Center, Peking Union Medical College Hospital, 
      Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 
      China.
FAU - Pang, Junyi
AU  - Pang J
AD  - Department of Pathology, State Key Laboratory of Complex Severe and Rare Disease, 
      Molecular Pathology Research Center, Peking Union Medical College Hospital, 
      Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 
      China.
FAU - Shi, Xiaohua
AU  - Shi X
AD  - Department of Pathology, State Key Laboratory of Complex Severe and Rare Disease, 
      Molecular Pathology Research Center, Peking Union Medical College Hospital, 
      Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 
      China.
FAU - Liang, Zhiyong
AU  - Liang Z
AD  - Department of Pathology, State Key Laboratory of Complex Severe and Rare Disease, 
      Molecular Pathology Research Center, Peking Union Medical College Hospital, 
      Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 
      China.
LA  - eng
PT  - Journal Article
DEP - 20211021
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC8566736
OTO - NOTNLM
OT  - Cervix
OT  - NTRK fusion
OT  - PD-L1
OT  - immune checkpoint inhibitor
OT  - mismatch repair system
OT  - small cell neuroendocrine carcinoma
OT  - targeted therapy
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/11/09 06:00
MHDA- 2021/11/09 06:01
PMCR- 2021/01/01
CRDT- 2021/11/08 06:47
PHST- 2021/08/03 00:00 [received]
PHST- 2021/10/05 00:00 [accepted]
PHST- 2021/11/08 06:47 [entrez]
PHST- 2021/11/09 06:00 [pubmed]
PHST- 2021/11/09 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2021.752453 [doi]
PST - epublish
SO  - Front Oncol. 2021 Oct 21;11:752453. doi: 10.3389/fonc.2021.752453. eCollection 
      2021.